Evidence map›Paper›PMID 41736575›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.

Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xinchao WuDepartment of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID https://orcid.org/0009-0003-9265-9565
Mengtao SunDepartment of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Lusheng LiDepartment of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Jieqiong WangDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Shibiao WanDepartment of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0003-0661-2684

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Leveraging Heterogenous Common Fund Data Sets and Beyond for Identifying Lung Cancer SubtypesR03OD038391 · OD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WAN, SHIBIAO, WANG, JIEQIONG · 2024 to 2024
$307k
American Cancer Society IRG-22-146-07-IRGChild Health Research Institute, University of Nebraska Medical CenterFred and Pamela Buffett Cancer Center CA036727National Science Foundation 2500836NCI NIH HHS P30 CA036727NCI NIH HHS P30CA036727NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P20GM103427NIH HHS R03 OD038391NIH Office of the Director R03OD038391
6 · The paper itself

Abstract

Cancer immunotherapy, which leverages the immune system to combat tumor cells, has made significant advancements in oncology treatment in recent years. Yet significant challenges remain in predicting treatment responses and understanding mechanisms of resistance. Artificial intelligence (AI) and machine learning (ML) provide powerful tools to address these challenges, enabling breakthroughs in patient stratification, biomarker discovery, and treatment strategy optimization. While remarkable progress has been made in developing deep learning frameworks, including large language models (LLMs) to integrate the exponentially growing multi-omics biomedical data for cancer immunotherapy, little effort has been made to systematically and comprehensively summarize these developments or critically evaluate their translational potential. To fill these gaps, this review comprehensively examines the current landscape and future directions of AI/ML applications in cancer immunotherapy. Specifically, we discuss four key areas in AI for cancer immunotherapy: (1) patient stratification, (2) biomarker discovery, (3) treatment strategy optimization, and (4) foundation models and LLMs for cancer immunotherapy. In addition, we also critically discuss current limitations and future directions for existing AI approaches for cancer immunotherapy, highlighting the actionable insights and roadmaps to accelerate the integration of AI/ML into precision cancer immunotherapy.

Indexed as

Artificial IntelligenceImmunotherapyNeoplasmsHumansLarge Language ModelsMachine Learningartificial intelligencecancer immunotherapyfoundation modelmachine learningmulti‐omics

Identifiers

PMID41736575
PMCPMC13292183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.